Anavex Life Sciences (AVXL) Price & Analysis

Compare

1,729 Followers

AVXL Stock Chart & Stats

$4.41

-$1.39(-10.33%)

At close: Jan 08 4:00 PM EST

$4.41

-$1.39(-10.33%)

Day’s Range― - ―

52-Week Range$2.86 - $14.44

Previous CloseN/A

Volume1.46M

Average Volume (3M)3.43M

Market Cap

$387.77M

Enterprise Value$661.88M

Total Cash (Recent Filing)$101.16M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Feb 05, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding89,348,110

10 Day Avg. Volume2,682,924

30 Day Avg. Volume3,432,981

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)8.00

Price to Sales (P/S)0.00

P/FCF Ratio-19.44

Enterprise Value/Market Cap1.71

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.47

Forecast

1Y Price Target

$20.00

Price Target Upside353.51% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.52

Revenue Forecast (FY)$221.71M

Bulls Say, Bears Say

Bulls Say

Clinical Data And ResearchBlarcamesine appears to have the ability to meaningfully slow or delay disease progression in AD.

Market PotentialPossible blarcamesine EU market entry next year with a potential regulatory decision on the Marketing Authorization Application soon.

Regulatory DevelopmentsThere is recent precedent in the Alzheimer's disease indication—most notably with respect to the case of lecanemab—for a negative trend vote reversal and eventual regulatory approval.

Bears Say

Market SentimentThe short percentage of float has held steady at approximately 30% for over 6 months, indicating significant bearish sentiment in the market.

Regulatory ChallengesThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recorded a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine.

Stock Valuation ImpactAnavex's current stock value is entirely dependent on the decision from the European Medicines Agency (EMA) regarding the approval of blarcamesine in Alzheimer's disease.

Anavex Life Sciences News

Anavex reports Q4 EPS (11c), consensus (15c)

“There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million...

15d ago

AVXL

Anavex sees cash runway of over three years

Cash and cash equivalents of $102.6 million at September 30, 2025 compared to $132.2 million at September 30,...

15d ago

AVXL

Options Volatility and Implied Earnings Moves This Week, November 24 – November 26, 2025

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Nio (NIO), Zoom Video...

16d ago

Anavex price target lowered to $20 from $42 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Anavex (AVXL) to $20 from $42 and keeps a Buy...

21d ago

AVXL

Unusually active option classes on open November 17th

Unusual total active option classes on open include: NB Bancorp Inc (NBBK), Newell Brands (NWL), Cadiz (CDZI), SSR...

23d ago

CDE

NWL

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday. ...

25d ago

DIA

MRK

Midday Fly By: Walmart names new CEO, Merck acquires Cidara

The major averages were mixed near noon, as the Dow dropped while the S&P 500 and the Nasdaq...

26d ago

Anavex trading resumes

09:38 EST Anavex (AVXL) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

26d ago

AVXL

Anavex trading halted, volatility trading pause

09:33 EST Anavex (AVXL) trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

26d ago

AVXL

Why Is Anavex Life Sciences Stock (AVXL) Down Today?

Anavex Life Sciences stock dove on Friday after the company revealed a regulatory update. ...

26d ago

AVXL

Anavex to request re-examination of CHMP opinion on MAAA for blarcamesine

Anavex (AVXL) Life Sciences provides a regulatory update on blarcamesine for early Alzheimer’s disease. The Company was informed...

26d ago

AVXL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: DEFIANCE DAILY TARGET 2X...

29d ago

NFE

RUM

Anavex Life Sciences: Strategic Positioning and Potential Reversal in Alzheimer’s Treatment Boost Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences and keeping the price...

12d ago

AVXL

Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry

Anavex Life Sciences (AVXL) has disclosed a new risk, in the Litigation & Legal Liabilities category. Anavex Life...

13d ago

AVXL

AVXL FAQ

What was Anavex Life Sciences’s price range in the past 12 months?

Anavex Life Sciences lowest stock price was $2.86 and its highest was $14.44 in the past 12 months.

What is Anavex Life Sciences’s market cap?

Anavex Life Sciences’s market cap is $387.77M.

When is Anavex Life Sciences’s upcoming earnings report date?

Anavex Life Sciences’s upcoming earnings report date is Feb 05, 2026 which is in 57 days.

How were Anavex Life Sciences’s earnings last quarter?

Anavex Life Sciences released its earnings results on Nov 25, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.

Is Anavex Life Sciences overvalued?

According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anavex Life Sciences pay dividends?

Anavex Life Sciences does not currently pay dividends.

What is Anavex Life Sciences’s EPS estimate?

Anavex Life Sciences’s EPS estimate is -0.12.

How many shares outstanding does Anavex Life Sciences have?

Anavex Life Sciences has 89,348,110 shares outstanding.

What happened to Anavex Life Sciences’s price movement after its last earnings report?

Anavex Life Sciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 12.338%.

Which hedge fund is a major shareholder of Anavex Life Sciences?

Currently, no hedge funds are holding shares in AVXL

Anavex Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.11%

Trailing 12-Months

Asset Growth

-23.42%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences (AVXL) Earnings & Revenues

Historic Earnings Reports

AVXL Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive advancements in clinical trials and strong financial positioning, contrasted by the setback of a negative CHMP opinion in Europe for blarcamesine and a decrease in R&D spending. Despite the challenges, the company remains optimistic about its scientific data and future regulatory discussions.View all AVXL earnings summaries

AVXL Stock 12 Month Forecast

Average Price Target

$20.00

▲(353.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.97,8.895384615384614,9.82076923076923,10.746153846153845,11.67153846153846,12.596923076923076,13.522307692307692,14.447692307692307,15.373076923076923,16.298461538461538,17.223846153846154,18.14923076923077,19.074615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.97,8.895384615384614,9.82076923076923,10.746153846153845,11.67153846153846,12.596923076923076,13.522307692307692,14.447692307692307,15.373076923076923,16.298461538461538,17.223846153846154,18.14923076923077,19.074615384615385,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.97,8.895384615384614,9.82076923076923,10.746153846153845,11.67153846153846,12.596923076923076,13.522307692307692,14.447692307692307,15.373076923076923,16.298461538461538,17.223846153846154,18.14923076923077,19.074615384615385,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >